DTU Logo
About the DTU | News | Staff | Alumni | Contact/Find us

HTA report on self-monitoring of blood glucose

25-Jun-2009

We have found no convincing evidence to recommend routine use of SMBG by reasonably well-controlled, non-insulin-treated patients with type 2 diabetes. The specific advantages of monitoring identified by patients need to be placed in the context of a decline in compliance in the more intensive monitoring group and, at best, a small reduction in HbA1c. Neither the within-trial economic analysis nor the long-term modelling supports SMBG as a cost-effective intervention for all non-insulin-treated patients with type 2 diabetes. However, a clinically important benefit for specific subgroups of patients in initiating good glycaemic control cannot be excluded without further research.


[Link]